Association of Serum Irisin Level with BMI, Glycemic Control and Inflammatory Marker in Iraqi Patients with Type 2 Diabetes Mellitus

Abstract

Background: Type 2 diabetes mellitus is a significant global health concern, with dramatically increased cases over all region. Irisin, a secreted novel myokine, is produced by skeletal muscles and promote energy expenditure. This hormone may play an important role in the metabolism of glucose and lipids and improve insulin resistance. Furthermore, it could be effective in treating disease such as inflammation, apoptosis, oxidative stress and atherosclerosis by inhibiting the expression and release of proinflammatory cytokines. Objectives: assess level of irisin in type 2 diabetes mellitus. Also, assess the association between irisin and glycemic control, Body Mass Index and C-Reactive Protein. Methods: this case-control study involves 62 participants, 41 diabetic cases and 21 control subjects. Patient are diagnosed according to American Diabetes Association criteria. Irisin hormone assay was measured by using Human Irisin ELISA. C-Reactive Protein analysis was measured by CRP Rapid Quantitative Test; the result is considered as high or normal CRP. Results: irisin level in diabetic group is higher than control group with highly significant difference (171.03 vs 107.9, p=0.008). The correlation between irisin hormone in diabetic group show negative correlation with BMI but without significant difference (r=-0.341, p=0.29), also HbA1c shows negative correlation (but weak) without significant difference (r=-0.28, p=0.07). irisin hormone level in patients with high and normal CRP level show no significant differences (p=0.4).

Conclusion: increased irisin level in diabetic patients, no significant negative correlation between irisin with BMI and Hba1c, no significant difference between irisin in high and normal level of CRP.